Abstracts

Integrase Resistance Correlates of Response to Dolutegravir (DTG) Through 48 Weeks

Background: Phenotypic and genotypic correlates of antiviral response (AR) derived from clinical investigation characterize an antiretroviral’s (ART) ability to inhibit HIV. The VIKING-3 and VIKING-4 (V3/4) studies examined DTG 50mg twice-daily in patients with resistance to multiple ART’s, including integrase inhibitors (INI). Baseline Integrase (IN) genotypes and phenotypes were assessed to identify correlates to AR.…

Discordant Predictions Could Impact Dolutegravir Use Upon Raltegravir Failure

Background: The latest integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) has been approved for HIV-1 patients with resistance to INSTIs raltegravir (RAL) and elvitegravir (EVG). While expanding therapeutic options, the decision for DTG use in this setting should be informed by the presence of baseline mutational patterns. Methods: Integrase sequences of 216 HIV-1 infected patients…

Integrase S119P Mutation Correlates With Disease Progression in HIV-1 Naïve Patients

Background: Recent finding showed that specific HIV integrase (IN) polymorphisms at positions S119, T122 and R231 affect integration site targeting in the host genome. Moreover, mutations at position S119 have been associated with HLA selection. We thus characterized the prevalence of IN polymorphisms at these positions and their association with CD4 cell count and HIV-RNA…

Acute Infections, Cost and Time to Reporting of HIV Test Results in US State Public Health Laboratories

Background: In 2014, CDC recommended an HIV diagnostic algorithm (repeatedly reactive [RR] 4th-generation immunoassay [IA] that detects HIV-1 antigen and HIV antibody, followed by an HIV-1/HIV-2 differentiation antibody IA, and when negative or indeterminate, an HIV-1 nucleic acid test [NAT]) to detect acute infections and to reduce misclassification of HIV-2 as HIV-1 infections. In three…

The POC Alere q HIV-1/2 Detect Test for Detection and Quantification of HIV-2

Background: Rapid point-of-care (POC) nucleic acid testing (NAT) that can detect, differentiate and quantify HIV-1 and HIV-2 RNA/DNA has the potential to improve the cascade of care and antiretroviral therapy monitoring. In addition, the new 4th-generation CDC algorithm for HIV diagnostic testing specifies differential HIV-1 and HIV-2 serologic and nucleic acid testing, but there are…

Performance of HIV Viral Load with Dried Blood Spots in Children on ART in Mozambique

Background: The World Health Organization (WHO) recommends using HIV viral load (VL) to monitor antiretroviral treatment (ART) and detect virologic failure (VF) (>1000 copies/mL). However, the gold standard sample, plasma, is challenging to process for patients living in remote areas due to requirements for plasma separation, transportation, and storage. Dried blood spots collected by finger…

Cost-Effectiveness of Pooled PCR Testing of Dried Blood Spots for Infant HIV Diagnosis

Background: Early diagnosis and initiation on antiretroviral therapy is important for the improved prognosis of HIV infected infants. In resource limited settings, restricted access to qualitative polymerase chain reaction (PCR) amplifies the need for diagnostic tools with improved cost-effectiveness. This study investigates the potential savings achievable by pooling dried blood spots (DBS) for PCR testing,…

Evaluating Dried Blood Spot Performance in Assessing HIV Treatment Failure in Uganda

Background: HIV RNA viral load (VL) testing for patients on antiretroviral therapy (ART) has increasingly been recognized as a key component of patient monitoring, even in low-resource settings. However, due to financial and technical constraints, the routine implementation of virologic testing remains rare in most sub-Saharan Africa health facilities. Dried blood spots (DBS) have emerged…

Improved Viral Load Monitoring Capacity With Rank-Based Algorithms for Pooled Assays

Background: HIV viral load (VL) monitoring is recommended globally for patients on antiretroviral therapy (ART). However, cost and infrastructure in resource limited settings (RLS) still limit widespread implementation of this guideline. VL pooling reduces the number of assays needed to ascertain individuals’ VL. However, existing pooling methods ignore information from routinely-collected clinical markers (RCMs), such…